The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes

Trial Profile

The Use of Glutamic Acid Decarboxylase (GAD) and Gamma-Amino Butyric Acid (GABA) in the Treatment of Type I Diabetes

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2018

At a glance

  • Drugs GAD65 vaccine (Diamyd) (Primary) ; Gamma aminobutyric acid (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms GABA/ DIAMYD
  • Most Recent Events

    • 04 Jul 2018 According to a Diamyd Medical media release, results are expected to be presented in the final quarter of 2019.
    • 04 Jul 2018 According to a Diamyd Medical media release, 56 patients have been completed the entire trial.
    • 04 Jul 2018 Status changed from recruiting to active, no longer recruiting, according to a Diamyd Medical AB media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top